Stock Events

Stock Events

Immunic 

$12.76
124
-$1.48-10.39% Thursday 20:00
+$0.20+1.57%Thursday 23:35After hours

Statistics

Day High
12.88
Day Low
12.7
52W High
17.43
52W Low
5.06
Volume
16,292
Avg. Volume
-
Mkt Cap
174.1M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.16
-0.82
-0.47
-0.13
Expected EPS
-0.965127
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-97.17MNet Income

Analyst Ratings

20.70Average Price Target
The highest estimate is 45.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMUX. It's not an investment recommendation.
NVIDIA
16
NVDA
Amazon
13
AMZN
Microsoft
12
MSFT
AMD
12
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on discovering, developing, and delivering therapies for neurological diseases, similar to Immunic's focus on immune-mediated diseases.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the research and development of therapeutic treatments for a variety of diseases, including those in Immunic's target areas.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in the same biopharmaceutical field, focusing on immunology and chronic diseases, competing directly with Immunic's product pipeline.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for illnesses in areas that overlap with Immunic's research, such as inflammatory diseases.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb, having acquired Celgene, continues to be a competitor with a strong portfolio in immunology and oncology, areas relevant to Immunic.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals specializes in developing medications for autoimmune diseases and inflammatory conditions, directly competing with Immunic's therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in creating new therapies for treating cystic fibrosis and other serious diseases, competing for similar patient populations as Immunic.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that has a broad range of products competing across several of Immunic's key areas, including immunology.
Pfizer
PFE
Mkt Cap159.36B
Pfizer operates globally in various therapeutic areas, including inflammation and immunology, making it a competitor to Immunic in the biopharmaceutical sector.

About

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Show more...
CEO
Erik Lundgren
Employees
95
Country
United States
ISIN
US4525EP2001
WKN
000A428WY

Listings

F
DE
10V.F
STU
DE
10V.STU
MU
DE
10V.MU
XNAS
US
IMUX

0 Comments

Share your thoughts

FAQ

What is Immunic stock price today?▼
The current price of IMUX is $12.76 USD — it has decreased by -10.39% in the past 24 hours. Watch Immunic stock price performance more closely on the chart.
What is Immunic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immunic stocks are traded under the ticker IMUX.
Is Immunic stock price growing?▼
IMUX stock has fallen by -17.14% compared to the previous week, the month change is a -9.18% fall, over the last year Immunic has showed a +65.71% increase.
What is Immunic market cap?▼
Today Immunic has the market capitalization of 174.1M
When is the next Immunic earnings date?▼
Immunic is going to release the next earnings report on October 29, 2026.
What were Immunic earnings last quarter?▼
IMUX earnings for the last quarter are -0.8 USD per share, whereas the estimation was -1.16 USD resulting in a +31.32% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immunic revenue for the last year?▼
Immunic revenue for the last year amounts to 0 USD.
What is Immunic net income for the last year?▼
IMUX net income for the last year is -97.17M USD.
How many employees does Immunic have?▼
As of September 04, 2026, the company has 95 employees.
In which sector is Immunic located?▼
Immunic operates in the Health & Wellness sector.
When did Immunic complete a stock split?▼
The last stock split for Immunic was on April 27, 2026 with a ratio of 1:10.
Where is Immunic headquartered?▼
Immunic is headquartered in NEW YORK, United States.